BMY
Price
$44.16
Change
-$0.76 (-1.69%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
91.41B
36 days until earnings call
GILD
Price
$113.67
Change
-$0.73 (-0.64%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
141.95B
29 days until earnings call
Interact to see
Advertisement

BMY vs GILD

Header iconBMY vs GILD Comparison
Open Charts BMY vs GILDBanner chart's image
Bristol-Myers Squibb
Price$44.16
Change-$0.76 (-1.69%)
Volume$161.45K
Capitalization91.41B
Gilead Sciences
Price$113.67
Change-$0.73 (-0.64%)
Volume$118.09K
Capitalization141.95B
BMY vs GILD Comparison Chart in %
Loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMY vs. GILD commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and GILD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (BMY: $44.91 vs. GILD: $114.40)
Brand notoriety: BMY and GILD are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 138% vs. GILD: 113%
Market capitalization -- BMY: $91.41B vs. GILD: $141.95B
BMY [@Pharmaceuticals: Major] is valued at $91.41B. GILD’s [@Pharmaceuticals: Major] market capitalization is $141.95B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $669.64B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • GILD’s FA Score: 3 green, 2 red.
According to our system of comparison, GILD is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 3 bullish TA indicator(s).

  • BMY’s TA Score: 4 bullish, 6 bearish.
  • GILD’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GILD is a better buy in the short-term than BMY.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а -3.09% price change this week, while GILD (@Pharmaceuticals: Major) price change was +3.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.08%. For the same industry, the average monthly price growth was +0.15%, and the average quarterly price growth was +13.52%.

Reported Earning Dates

BMY is expected to report earnings on Oct 30, 2025.

GILD is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.08% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($142B) has a higher market cap than BMY($91.4B). GILD has higher P/E ratio than BMY: GILD (22.70) vs BMY (18.04). GILD YTD gains are higher at: 26.477 vs. BMY (-17.781). GILD has less debt than BMY: GILD (24.9B) vs BMY (50.9B).
BMYGILDBMY / GILD
Capitalization91.4B142B64%
EBITDA15.1BN/A-
Gain YTD-17.78126.477-67%
P/E Ratio18.0422.7079%
Revenue47.7BN/A-
Total Cash13.6BN/A-
Total Debt50.9B24.9B204%
FUNDAMENTALS RATINGS
BMY vs GILD: Fundamental Ratings
BMY
GILD
OUTLOOK RATING
1..100
5370
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
10012
SMR RATING
1..100
3329
PRICE GROWTH RATING
1..100
6350
P/E GROWTH RATING
1..100
46100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (6) in the Pharmaceuticals Major industry is in the same range as GILD (15) in the Biotechnology industry. This means that BMY’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for BMY (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than BMY’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is in the same range as BMY (33) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to BMY’s over the last 12 months.

GILD's Price Growth Rating (50) in the Biotechnology industry is in the same range as BMY (63) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to BMY’s over the last 12 months.

BMY's P/E Growth Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (100) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYGILD
RSI
ODDS (%)
Bullish Trend 2 days ago
53%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
59%
Momentum
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
46%
MACD
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 2 days ago
36%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
43%
Advances
ODDS (%)
Bullish Trend 22 days ago
54%
Bullish Trend 6 days ago
60%
Declines
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 9 days ago
48%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
42%
Aroon
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
55%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FDMT7.610.21
+2.84%
4D Molecular Therapeutics
GAP22.860.25
+1.11%
Gap Inc (The)
TECTP10.79N/A
N/A
Tectonic Financial
VERA25.96-0.15
-0.57%
Vera Therapeutics
SPCB12.54-0.24
-1.88%
SuperCom Ltd

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
-0.16%
PFE - BMY
54%
Loosely correlated
+0.37%
MRK - BMY
50%
Loosely correlated
-0.55%
GILD - BMY
48%
Loosely correlated
+1.70%
NVS - BMY
44%
Loosely correlated
-0.44%
GSK - BMY
43%
Loosely correlated
-0.95%
More

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+1.70%
BMY - GILD
48%
Loosely correlated
-0.16%
GSK - GILD
45%
Loosely correlated
-0.95%
BIIB - GILD
42%
Loosely correlated
-0.96%
NVS - GILD
42%
Loosely correlated
-0.44%
AMGN - GILD
41%
Loosely correlated
+0.28%
More